Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Second primary cancers after small-cell lung cancer]

J C Soria1, J M Bréchot, B Lebeau

  • 1Service de pneumologie, Hôtel-Dieu, Paris, France.

Bulletin Du Cancer
|August 1, 1997
PubMed
Summary

Second primary malignancies (SPMs) occurred in patients with small cell lung cancer (SCLC). These secondary cancers, including lung and other types, significantly impacted survival, with median survival of 6 months for synchronous and 4 months for metachronous SPMs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cobalt Stabilization through Mesopore Confinement on TiO<sub>2</sub> Support for Fischer-Tropsch Reaction.

ACS applied energy materials·2023
Same author

Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.

ESMO open·2022
Same author

Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Epidemiology

Background:

  • Small cell lung cancer (SCLC) is an aggressive malignancy.
  • Understanding the risk and patterns of second primary malignancies (SPMs) in SCLC survivors is crucial for long-term management.

Purpose of the Study:

  • To investigate the incidence and types of second primary malignancies (SPMs) in patients diagnosed with small cell lung cancer (SCLC).
  • To analyze the survival outcomes associated with synchronous (SSPM) and metachronous (MSPM) second primary malignancies in SCLC patients.

Main Methods:

  • Retrospective review of medical records for 1,371 patients with small cell lung cancer (SCLC) treated between 1983 and 1994.
  • Identification and classification of synchronous (SSPM) and metachronous (MSPM) second primary malignancies.

Related Experiment Videos

  • Survival analysis following the diagnosis of SPMs.

    • Main Results:

    • Eight synchronous SPMs (SSPMs) and 8 metachronous SPMs (MSPMs) were identified.
    • SSPMs included non-small cell lung cancer (6 patients), head and neck cancer (1), and esophageal cancer (1). Median survival post-SSPM diagnosis was 6 months.
    • MSPMs, diagnosed 1-6 years post-SCLC, included lung cancer (3), gastrointestinal malignancies (2), hematologic malignancy (1), prostate cancer (1), and head and neck cancer (1). Median survival post-MSPM diagnosis was 4 months.

    Conclusions:

    • The occurrence of second primary malignancies (SPMs) represents a notable clinical pattern in small cell lung cancer (SCLC) survivors.
    • Potential contributing factors for SPM development include tobacco use, genetic predispositions, and the effects of multimodality cancer treatments.
    • SPMs are associated with poor prognosis in SCLC patients, underscoring the need for vigilant long-term surveillance and research into underlying mechanisms.